Recruiting
Phase 1

SI-B037

Sponsor:

SystImmune Inc.

Code:

NCT07940881

Conditions

Locally Advanced /Metastatic Solid Tumors

Locally Advanced / Metastatic Solid Tumors

First in Human

Metastatic Solid Cancers

Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SI-B037

Study Details

Brief summary:

The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.

Conditions

Locally Advanced /Metastatic Solid Tumors

Locally Advanced / Metastatic Solid Tumors

First in Human

Metastatic Solid Cancers

Non Small Cell Lung Cancer

Study ID

NCT07940881

Start date

Aug 24, 2026

Status verified date

Nov, 2026

Completion date

Nov, 2029

Anticipated

Primary completion date

Nov, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Signed the informed consent form voluntarily and agreed to follow the trial requirements.
  • Male or Female Age ≥18 years.
  • Has a life expectancy of ≥3 months.
  • Subjects with documented locally advanced or metastatic solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 line of standard therapy in the metastatic setting.
  • At least 1 measurable lesion based on RECIST 1.1
  • Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
  • Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V6.0.
  • Has no serious cardiac dysfunction and left ventricular ejection fraction ≥50%.
  • Has adequate organ function, before enrollment
  • Sexually active fertile participants and their partners must agree to use highly effective methods of contraception (defined in Appendix 5 of the protocol) during the course of the study and for 4 months for men and 7 months for women after the last dose of study treatment.
  • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening and must be nonlactating.

Exclusion Criteria:

  • Chemotherapy, biological therapy, immunotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; radical radiotherapy, major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral drugs such as capecitabine, or palliative radiotherapy within 2 weeks prior to initial administration.
  • Received systemic immunostimulatory therapy (such as IFN-α, IL-2) within 4 weeks prior to the first dose or is still within 5 half-lives of the treatment (whichever is longer).
  • Participants with history of severe heart disease, such as symptomatic congestive heart failure Grade ≥2 (CTCAE 6.0), New York Heart Association (NYHA) Grade ≥2 heart failure at any time, history of myocardial infarction, or unstable angina pectoris within 6 months before enrollment.
  • Grade ≥ 3 toxicity related to anti-angiogenic therapy (except for fever and other toxicities that the investigator believes does not pose a safety risk to trial participants) when receiving anti-angiogenic therapy in the past.
  • Participant with active or untreated hemorrhagic CNS lesions.
  • Participants with pre-existing Grade ≥2 peripheral neuropathy

Study Design

Enrollment

400 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Experimental: Experimental SI-B037

SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks

Interventions

SI-B037

SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks

Primary outcome measure

  • Participants with Dose-Limiting Toxicities [ Time Frame: 24 months ]

Central Contacts and Locations

Locations

NEXT Oncology

Recruiting

Houston, Texas, United States, 77054

Contacts

NEXT Oncology Study Coordinator

210-568-4397

More Information

Sponsor

SystImmune Inc.

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • PD-1
  • VEGF
  • first in human

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by SystImmune Inc. on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.